BURLINGTON, Mass. / Sep 14, 2023 / Business Wire / Butterfly Network, Inc., a digital health company transforming care through the power of portable, semiconductor-based ultrasound technology and intuitive software, issued a statement on the impact of its comprehensive point-of-care ultrasound (POCUS) solution, Butterfly iQ+, in advancing medical education curriculum nationally. The update follows news from Indiana University School of Medicine (IUSM) earlier this week announcing its investment in Butterfly iQ+ technology and enhanced training for its medical students, as well as faculty, residents and fellows across family medicine, internal medicine, emergency medicine, anesthesia, OB-GYN, surgery and critical care.
Butterfly’s POCUS technology can be found onsite at the majority of U.S. medical schools today, with an increasing number of programs adopting a hands-on, one-probe-per-student training model. Butterfly’s device sales into U.S. medical schools more than doubled in volume in the first half of 2023 over 2022, as schools continue to realize the value of POCUS.
IUSM now leads the charge of academic institutions driving a fundamental shift in medical education. The school’s exemplary deployment expands on the one-probe-per-student training model by also leveraging Butterfly’s medical education solution to prepare residents, fellows, and faculty with devices and POCUS skills to ensure lasting adoption that carries through to evolved standards of patient care in their health system.
In the school’s news release, IUSM’s Executive Associate Dean for Educational Affairs and Institutional Improvement and Chief Academic Officer, Paul M. Wallach, MD, commented, “Many physicians consider POCUS the stethoscope of the future, and as such, its use is rapidly growing in medical practices across the country… We have created an ecosystem where students, faculty and residents can all collaborate, learn and teach one another.”
“With over half of all U.S. medical schools using POCUS to train students, and more adopting Butterfly technology every day, it’s become inevitable that the next generation of doctors will all have ultrasound skills and use POCUS in standard assessment across specialties,” said Joseph DeVivo, President, Chief Executive Officer and Chairman of Butterfly Network. “Butterfly is making every effort to propel this movement forward to continue capitalizing on medical education, while helping the current generation of doctors get up to speed and investing in innovation to fully realize the power of our technology in adjacent markets.”
To learn more about Butterfly’s solution for medical schools visit https://www.butterflynetwork.com/medical-schools
About Butterfly Network
Founded by Dr. Jonathan Rothberg in 2011 and listed on the New York Stock Exchange through a business combination with Longview Acquisition Corp., Butterfly created the world's first handheld, single probe whole-body ultrasound system using semiconductor technology, the Butterfly iQ+. Butterfly's mission is to democratize medical imaging and contribute to the aspiration of global health equity, making high-quality ultrasound affordable, easy-to-use, globally accessible, and intelligently connected, including for the 4.7 billion people around the world lacking access to ultrasound. Through its proprietary Ultrasound-on-Chip™ technology, Butterfly is paving the way for earlier detection and remote management of health conditions around the world. The Butterfly iQ+ can be purchased today by trained healthcare practitioners in areas including, but not limited to, parts of Africa, Asia, Australia, Europe, North America and South America; to learn more about available countries, visit: butterflynetwork.com/choose-your-country.
Last Trade: | US$3.12 |
Daily Change: | -0.40 -11.36 |
Daily Volume: | 4,101,665 |
Market Cap: | US$582.320M |
November 01, 2024 October 08, 2024 September 17, 2024 August 01, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB